Table 5.
Selected clinical trials that incorporate next-generation BCL2 inhibitors in experimental therapy of hematologic malignancies.
| Next-Generation BCL2 Inhibitors +/− Other Agents | Mode of Action of Agent(s) Used in Combination with the Next-Generation BCL2 Inhibitor | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|
| BGB-11417 | Single-agent BCL2 inhibitor | 1 | mature B-cell malignancies | May 2024 | NCT04883957 |
| BGB-11417 +/− zanubrutinib | Bruton tyrosine-kinase inhibitor | 1 | mature B-cell malignancies | August 2023 | NCT04277637 |
| BGB-11417 | Single-agent BCL2 inhibitor | 1 | Myeloid malginancies | February 2024 | NCT04771130 |
| BGB-11417 +/− Carfilzomib + Dexamethasone | Proteasome inhibitor + corticosteroid | 1/2 | MM | September 2025 | NCT04973605 |
| S65487 + Azacitidine | Hypomethylating agent | 1/2 | AML | March 2024 | NCT04742101 |
| S65487 | Single-agent BCL2 inhibitor | 1 | AML, B-NHL, MM, CLL | August 2023 | NCT03755154 |
| S65487/VOB560 + MIK665/S64315 | MCL1 inhibitor | 1 | HM | January 2025 | NCT04702425 |
| APG-2575 | Single-agent BCL2 inhibitor | 1 | CLL/SLL | January 2022 | NCT04215809 |
| APG-2575 + Pomalidomide/Dexamethasone or Daratumumab + Lenalidomide + Dexamethasone | Immunomodulatory agents pomalidomide and lenalidomide, anti-CD38 antibody daratumumab, corticosteroid dexamethasone | 1/2 | MM | December 2023 | NCT04942067 |
| APG-2575 a Azacitidine | Hypomethylating agent | 1 | AML | October 2023 | NCT04964518 |
| FCN-338 | Single-agent BCL2 inhibitor | 1 | CLL/SLL | June 2024 | NCT04682808 |
AML = acute myelogeneous leukemia; B-NHL = B-cell non-Hodgkin lymphoma; CLL = chronic lymphocytic leukemia; HM = hematologic malignancies; MM = multiple myeloma; SLL = small lymphocytic lymphoma.